Pds Biotechnology CORP 8-K filings

PDS Biotechnology Corporation stockholders approved an amendment to increase authorized common stock from 150 million to 300 million shares at the 2026 annual meeting.

PDS Biotechnology Corporation announced a strategic refocus on its PDS0301 program, discontinuing the VERSATILE-003 Phase 3 trial for PDS0101 and reporting a net loss of $9.8 million for Q2 2026.

PDS Biotechnology Corporation announced a strategic refocus on its PDS0301 program for metastatic colorectal cancer and will seek partnerships for PDS0101, discontinuing its Phase 3 trial.

PDS Biotechnology Corporation received a deficiency letter from Nasdaq for failing to meet the minimum $1.00 bid price requirement for its common stock.

PDS Biotechnology Corporation closed a $6 million promissory note and established a $50 million at-the-market offering program with YA II PN, LTD. and its affiliate Yorkville Securities, LLC.

PDS Biotechnology Corporation announced its 2026 Annual Meeting of Stockholders will be held on August 10, 2026, with a June 25, 2026 deadline for stockholder proposals.

PDS Biotechnology Corporation announced it has regained compliance with Nasdaq's minimum bid price requirement, closing a deficiency matter.

PDS Biotech reports Q1 2026 financial results, highlighting clinical advancements in cancer immunotherapies and a reduced net loss.

PDS Biotechnology has entered into a $6 million securities purchase agreement and initiated an at-the-market offering program while retiring existing senior secured debt.

PDS Biotechnology released an updated corporate presentation detailing progress on its Versamune and PDS01ADC immunotherapy platforms.

PDS Biotechnology Corporation reports promising interim Phase 2 clinical trial data for its PDS01ADC immunocytokine in metastatic colorectal cancer patients.

PDS Biotech reported a narrower 2025 net loss, amended its PDS0101 Phase 3 to use PFS for an accelerated approval path, highlighted encouraging PDS01ADC Phase 2 data, and ended the year with $26.7M in cash.

PDS Biotechnology Corporation received a deficiency letter from Nasdaq for failing to meet the minimum $1.00 bid price requirement, initiating a 180-day compliance period.

PDS Biotechnology updates corporate presentation highlighting PDS0101's compelling clinical results and accelerated approval pathway for HPV16-positive head and neck cancers.

PDS Biotech amends its Phase 3 VERSATILE-003 trial protocol to include progression-free survival as an interim primary endpoint for potential accelerated FDA approval of PDS0101.

PDS Biotechnology announced positive preliminary Phase 2 results for its IL-12 immunocytokine, PDS01ADC, in metastatic castration-resistant prostate cancer.

PDS Biotechnology Corporation announced a Notice of Allowance for a new U.S. patent covering its lead asset, PDS0101, extending market protections for over 20 years.

PDS Biotech submitted a protocol amendment to the FDA for its Phase 3 VERSATILE-003 trial, aiming for accelerated approval of PDS0101 by changing the primary endpoint to Progression Free Survival.

PDS Biotechnology Corporation announced the Japan Patent Office issued a new patent for PDS0101, strengthening its global intellectual property portfolio and extending protection into the 2040s.

PDS Biotechnology announced a Type C meeting with the FDA to discuss an accelerated approval pathway for its lead immunotherapy PDS0101 for HPV16-positive head and neck cancer, based on positive VERSATILE-002 trial results.

PDS Biotechnology reported Q3 2025 financial results and announced plans to seek an accelerated approval pathway for its lead immunotherapy, PDS0101, based on positive Phase 2 trial data.

PDS Biotechnology Corporation announced a registered direct offering of common stock and warrants, aiming to raise up to $11.1 million to advance its immunotherapy clinical trials.

PDS Biotechnology announced positive clinical and translational data for its investigational HPV16-targeted immunotherapy PDS0101 and immunocytokine PDS01ADC at the 2025 SITC Annual Meeting.

PDS Biotechnology Corporation requests an FDA meeting to explore an expedited approval pathway for PDS0101 in HPV16-positive Head and Neck Cancer, based on strong VERSATILE-002 trial data.

PDS Biotechnology announced a sub-analysis of its VERSATILE-002 trial showing PDS0101 significantly extended median overall survival in a difficult-to-treat head and neck cancer patient cohort.

PDS Biotechnology Corporation updated its corporate presentation, highlighting positive Phase 2 clinical trial results for PDS0101 in HPV16+ recurrent/metastatic HNSCC with a median overall survival of 39.3 months.

PDS Biotechnology announced final topline survival data from its VERSATILE-002 Phase 2 trial, showing a median overall survival of 39.3 months in HPV16-positive head and neck cancer patients.

PDS Biotechnology reported its second quarter 2025 financial results, showing an increased net loss but significant progress in its lead oncology clinical programs, including positive data from VERSATILE-002 and expansion of a colorectal cancer trial.

PDS Biotechnology Corporation announced that its PDS01ADC therapeutic, in combination with floxuridine, met pre-set criteria for expansion into Stage 2 of a Phase 2 clinical trial for metastatic colorectal cancer, led by the National Cancer Institute.

PDS Biotechnology Corporation has updated its corporate presentation, highlighting compelling Phase 2 clinical results for Versamune HPV in HPV16-positive recurrent/metastatic head and neck cancer and outlining plans for a pivotal Phase 3 trial.